The potential role of ribonucleic acid methylation in the pathological mechanisms of fragile X syndrome

Behav Brain Res. 2023 Aug 24:452:114586. doi: 10.1016/j.bbr.2023.114586. Epub 2023 Jul 17.

Abstract

Fragile X syndrome (FXS) is a common inherited cause of intellectual disabilities and single-gene cause of autism spectrum disorder (ASD), resulting from the loss of functional fragile X messenger ribonucleoprotein (FMRP), an RNA-binding protein (RBP) encoded by the fragile X messenger ribonucleoprotein 1 (FMR1) gene. Ribonucleic acid (RNA) methylation can lead to developmental diseases, including FXS, through various mechanisms mediated by 5-hydroxymethylcytosine, 5-methylcytosine, N6-methyladenosine, etc. Emerging evidence suggests that modifications of some RNA species have been linked to FXS. However, the underlying pathological mechanism has yet to be elucidated. In this review, we reviewed the implication of RNA modification in FXS and summarized its specific characteristics for facilitating the identification of new therapeutic targets.

Keywords: 5-methylcytosine (m(5)C); Fragile X syndrome; N(6)-methyladenosine (m(6)A); RNA modification; RNA-binding protein; Synaptic function.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autism Spectrum Disorder* / genetics
  • Fragile X Mental Retardation Protein / genetics
  • Fragile X Mental Retardation Protein / metabolism
  • Fragile X Syndrome* / genetics
  • Humans
  • Methylation
  • RNA / metabolism

Substances

  • RNA
  • Fragile X Mental Retardation Protein
  • FMR1 protein, human